Effect of modulation of MET with the small molecule inhibitor PF-04217903 on osteosarcoma metastasis in vivo. Background: Neuroblastoma is the most common extracranial solid tumor of childhood.
Immunotherapy with a chimeric antigen receptor (CAR) T-cell treatment targeting disialoganglioside GD2 may have a sustained antitumor effect in at least a proportion of pediatric patients with ...
Y-mAbs announces GD2-SADA clinical trial presentation for treating GD2-expressing tumors at the Advances in Neuroblastoma Research Meeting. Y-mAbs Therapeutics, Inc. has announced the presentation of ...
Please provide your email address to receive an email when new articles are posted on . The addition of the novel monoclonal antibody hu14.18K322A to induction chemotherapy significantly improved ...
Anti-disialoganglioside (GD2)-targeted third-generation chimeric antigen receptor T cells (GD2-CART01) have shown promising efficacy in children with high-risk metastatic, relapsed, and refractory ...
Pharmacogenomic diversity of clinically significant cancer treatment biomarkers in ancestrally diverse US population. Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras ...
Y-mAbs Therapeutics, Inc. has presented preclinical and translational pharmacokinetic data of their GD2-SADA bispecific fusion protein at the 2025 Society of Nuclear Medicine & Molecular Imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results